Cytovation announces appointment of Ole-Erik Iversen as Scientific Advisor
BERGEN, NORWAY, 20 January 2017 – Cytovation AS, a privately held biotech company developing CyPep-1 for the treatment of skin disorders announces the appointment of Professor Ole-Erik Iversen as Scientific Advisor.
Professor Iversen has been Professor of Gynecology & Obstetrics at University of Bergen since 1992, having previously held positions at the Department of Surgery at Molde Hospital; the Department of Gynecology & Obsetrics at Haukeland Hospital (University of Bergen); and was Research Fellow of The Norwegian Cancer Society (1984-1986).
Since 2000 he has been Principal Investigator (Norway) for several Phase II and III clinical trials for Merck and GSK (Gardasil and Cervarix). From 2007 he was also Member of Merck Scientific Advisory Committee on Second Generation HPV vaccines (Gardasil 9). He is currently Advisor to the Health Directorate and Norwegian Cancer Registry on use of HPV testing in triage and primary screening to replace cytology.
Cytovation CEO Kjell Inge Arnevig said: “We are pleased to welcome Professor Iversen to Cytovation. He joins the Company at an exciting time, with lead candidate CyPep-1 currently in pre-clinical development for the treatment of warts caused by the HPV virus. We are confident that Professor Iversen’s extensive experience in HPV vaccines will assist Cytovation to achieve its goals.”